University of Iowa Pharmaceuticals (UIP), a division of the University of Iowa College of Pharmacy, supported CeleCor Therapeutics, Inc. in collaboratively developing the formulation for its novel subcutaneous platelet GPIIb/IIIa inhibitor (RUC-4).  After successfully developing a formulation, UIP manufactured the cGMP first-in-man clinical trial supplies and performed release testing and stability assessment of the supplies.  UIP is pleased to see a drug development project it supported obtain successful initial clinical results.  Robert S. Hillman, President and CEO of CeleCor, "We are pleased with the results of our collaborative relationship with the University of Iowa Pharmaceuticals, and College of Pharmacy.  UIP offered Celecor expert formulation development and clinical manufacturing and analytical testing services of the highest quality.  RUC-4 is specifically designed for early and easy administration as a single subcutaneous injection by auto-injector so as to facilitate its use as the first point-of-contact treatment for STEMI. Further, the results of the Phase 1 study demonstrate that it can deliver rapid onset and limited duration platelet inhibition.  For more information go to: https://www.businesswire.com/news/home/20190925005021/en/CeleCor-Therapeutics-Announces-Positive-First-in-Human-Data-RUC-4.